XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL-Reference-Cited by-同舟云学术

XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL

Published:2022-08-19 Issue:21 Volume:28 Page:4600-4602
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Wang Naitao¹^ORCID,Hakimi A. Ari²³^ORCID,Chen Yu¹⁴⁵^ORCID

Affiliation:

1. 1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

2. 2Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

3. 3Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.

4. 4Department of Medicine, Genitourinary Service, Memorial Sloan Kettering Cancer Center, New York, New York.

5. 5Department of Medicine, Weill Cornell Medical College, New York, New York.

Abstract

Through analysis of the cancer dependency map of CRISPR and short hairpin RNA datasets, the antiapoptotic BCL-XL was found to be a selective dependency in kidney cancer. Among kidney cancers, BCL-XL inhibition is most active in those with a mesenchymal gene signature, which portends a poor prognosis and response to current therapies.See related article by Grubb et al., p. 4689

Funder

Division of Cancer Epidemiology and Genetics, National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-2104/3194483/ccr-22-2104.pdf

Reference21 articles.

1. A mesenchymal tumor cell state confers increased dependency on the BCL-XL anti-apoptotic protein in kidney cancer;Grubb;Clin Cancer Res,2022

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

4. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma;Tannir;Clin Cancer Res,2021

5. Sarcomatoid renal cell carcinoma: biology, natural history and management;Blum;Nat Rev Urol,2020